Dalpiciclib + Pyrotinib

DRUG2 trials

Sponsors

Peking University, Peking University Cancer Hospital & Institute

Conditions

Esophageal Squamous Cell Carcinoma

Phase 2

Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

RecruitingNCT06684600

Peking UniversityEsophageal Squamous Cell Carcinoma

Start: 2024-11-01End: 2027-10-30Target: 35Updated: 2024-11-12

Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer

Not yet recruitingNCT07653451

Peking University Cancer Hospital & InstituteEsophageal Squamous Cell Carcinoma

Start: 2026-07-01End: 2028-12-31Target: 90Updated: 2026-06-17